Fig. 3.

High infiltration of Foxp3⁺RORγt⁺ T cells indicates inferior responsiveness to adjuvant chemotherapy in gastric cancer. a For stage II/III gastric cancer patients, receiving ACT could lead to significantly better OS (P < 0.0001). b In Foxp3⁺RORγt⁺ T cells high subgroup, patients could not benefit from ACT (P = 0.5304). c In Foxp3⁺RORγt⁺ T cells low subgroup, however, patients could significantly benefit from ACT (P < 0.0001). d The interaction test between Foxp3⁺RORγt⁺ T cells infiltration and chemotherapeutic responsiveness indicated that patients with high infiltration of Foxp3⁺RORγt⁺ T cells might have inferior therapeutic responsiveness to ACT (P = 0.003)